|
#31
04.03.2005, 19:10
|
||||
|
||||
|
Öèòàòà:
À òîëêó îò ïèðàöåòàìà â ìåäèöèíñêîé ïðàêòèêå äåéñòâèòåëüíî íèêàêîãî. Çà ñâîþ ïðàêòèêó ìîãó ðó÷àòüñÿ. |
|
#32
04.03.2005, 19:11
|
|||
|
|||
|
Âû ïðîìîë÷àëè ïðî Ìåêñèäîë?
Âû áûëè íà ñàéòå? âû ïî ïðåæíåìó ñ÷èòàåòå ýòî ðåêëàìîé
Áåññïîðíî àâòîðåòåòíûìè èñòî÷íèêàìè âû ïîðàçèëè ìåíÿ, è ÷òî òåïåðü ñíÿòü ïèðàöåòàì ñ ïðîèçâîäñòâà? À Dr/Vad? îòâåòüòòå èñêðåííå è ïî ñóùåñòâó! |
|
#33
04.03.2005, 19:12
|
|||
|
|||
|
Äëÿ Dr.Vad---- Âû ïðîìîë÷àëè ïðî Ìåêñèäîë?
Âû áûëè íà ñàéòå? âû ïî ïðåæíåìó ñ÷èòàåòå ýòî ðåêëàìîé
Áåññïîðíî àâòîðåòåòíûìè èñòî÷íèêàìè âû ïîðàçèëè ìåíÿ, è ÷òî òåïåðü ñíÿòü ïèðàöåòàì ñ ïðîèçâîäñòâà? À Dr/Vad? îòâåòüòòå èñêðåííå è ïî ñóùåñòâó! |
|
#34
04.03.2005, 19:15
|
||||
|
||||
|
Íîðìàëüíàÿ ñèòóàöèÿ íà íà÷àëî òûñÿ÷åëåòèÿ ñ ïðîèçâîäíûìè ïèððîëèäîíà ñëåäóþùàÿ:
Aniracetam This drug was first investigated in the 1980s for cognition enhancement. It is still licensed in Italy and Switzerland but was withdrawn last year in Japan as a result of a negative study.(â Øâåéöàðñêîì êîìïåíäèóìå 2005 òîæå îòñóòñòâóåò)Clinical studies have been disappointing. Some controlled studies showed slight but significant effects in a variety of cognitive tasks but others, including a recent large randomised trial, did not. fasoracetam Early clinical studies suggest benefit, and fasoracetam is currently in phase III trials in Alzheimer's disease and in cerebrovascular disease. Nebracetam This pyrrolidone is awaiting marketing approval in Japan for cognitive enhancement but its development in Germany was abandoned. A few clinical studies have been carried out in dementia but the benefit has not been impressive and the findings have not been consistent. Clinical studies of its nootropic and neuroprotective potential are underway in Japan. Nefiracetam Nefiracetam is not yet licensed. Preclinical studies suggested promise in the areas of cognition enhancement and neuroprotection. Despite promising animal data and limited phase I clinical data, no phase II or III clinical studies have been published although these are underway. Oxiracetam This drug is licensed in Italy and Portugal as a cognitive enhancer, and is under development in other countries. Pramiracetam Pramiracetam is licensed in Italy as a cognitive enhancer but development in the USA has been discontinued. Èç òîãî æå îáçîðà - êàê âèäíî, èëè ïð-ò ëèöåíçèðîâàí â ñòðàíàõ, ãäå ìíîãî ÷òî ëèöåíçèðóåòñÿ (êàê è â Ðîññèè) èëè ïîçàáûòû-ïîçàáðîøåíû èëè ïîêà èññëåäóþòñÿ. |
|
#35
04.03.2005, 19:19
|
|||
|
|||
|
îáîëäåòü! â ýòî ñ òðóäîì âåðèòñÿ
Öèòàòà:
È ÂÑÅ! ÝÒÎ ÇÍÀÞÒ È ÇÀÊÐÛÂÀÞÒ ÃËÀÇÀ? ÏÐÎÄÎËÆÀß ÒÎÍÍÀÌÈ ÂÛÏÈÑÛÂÀÒÜ ÍÎÎÒÐÎÏÈË? |
|
#36
04.03.2005, 19:25
|
||||
|
||||
|
Ïî ìåêñèäîëó áîëüøå äàííûõ â ñåòè (îêîëî 70 â öèòèðóåìûõ èçäàíèÿõ), íî íà ëþäÿõ âñåãî 14, êîòîðûå ñêîðåå ïîäïàäàþò â ðóáðèêó: "à êóäà æå åãî åùå çàñóíóòü", íåæåëè ïðèëè÷íûå êëèí. èññëåäîâàíèÿ - òîëüêî íàçâàíèÿ (íå ÷èòàÿ òåçèñîâ, ìîãó íà 120% äîãàäàòüñÿ ÷òî â íèõ âñåõ ïîëó÷åíû òîëüêî ïîëîæèòåëüíûå ýôôåêòû, à ïîáî÷íûõ íè-íè, õîòÿ äàæå îò ïëàöåáî îíè èíîãäà îòìå÷àþòñÿ):
Effect of mexidol on efficacy of traditional therapy of sick sinus syndrome in adolescents Effect of mexidol on the course of post-traumatic epilepsy Effect of mexidol on oxidative stress in cerebral variant of hypertensive crisis Effectiveness of mexidol in acute pancreatitis Effect of mexidol on clinical and biochemical parameters of perinatal hypoxia in newborn children Ïîñëåäíÿÿ ñòàòüÿ îñîáåííî õàðàêòåðíà (íî è òðåâîæíà), ÷òî íå ãíóøàþòñÿ è ìàëûìè äåòüìè ðàäè ýêñïåðèìåíòîâ. |
|
#37
04.03.2005, 19:30
|
|||
|
|||
Öèòàòà:
íàøåé ìíîãîñòðàäàëüíîé? Äîðìîâûå ìèëëèàðäû â êàðìàíû íåèçâåñòíî êîìó? Ëîáèñòû? Èëè ïðîñòî âñåì íà âñå íàïëåâàòü? |
|
|
|
#38
04.03.2005, 19:32
|
||||
|
||||
|
Öèòàòà:
|
|
#39
04.03.2005, 19:39
|
|||
|
|||
|
óæå äàæå èíòåðåñíî
Öèòàòà:
Åñëè ìîæíî ïîïîäðîáíåå ÿ èìåþ ââèäó ïðåïàðàòû èç ñåðèè âûøåîáñóæäàåìûõ è åñëè åñòü èíôîðìàöèÿ ïî åæåãîäíîìó îáîðîòó â óñëîâíûõ åäèíèöàõ? |
|
#41
05.03.2005, 00:02
|
|||
|
|||
|
è âñåæå ïðîäîëæàåòå?
Öèòàòà:
ìîæåò óæå ïî èíåðöèè? èëè ÿ îøèáàþñü åñëè äà, òî èçâèíèòå! |
|
#43
05.03.2005, 00:20
|
||||
|
||||
|
Öèòàòà:
|
|
#44
05.03.2005, 02:54
|
|||
|
|||
Óâàæàåìûé Dr. Vad!
Âû íå ìîãëè áû âûëîæèòü, ïîëíûé òåêñò ñòàòüè Pyrrolidone derivatives by Simon Shorvon, ïîñêîëüêó, ìíå óäàëîñü íàéòè òîëüêî abstract: Simon Shorvon Lancet 2001; 358: 1885-92 Department of Clinical Neurology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, University College London, London WC1, UK; and National Neurological Institute, Singapore (Prof S Shorvon FRCP) The pyrrolidone (2-oxopyrrolidine) family of chemicals has been the subject of research for more than three decades. Experimental and clinical work first focused on their so-called nootropic effects; later came the possibilities for neuroprotection after stroke and use as antiepileptic agents. Piracetam, the first of the class, was developed by pioneering research by C Giurgea in the late 1960s, and it was he who coined the term "nootropic", to mean enhancement of learning and memory. The term is sometimes extended to include other actions such as neuroprotection. These properties, together with the lack of other generally adverse psychopharmacological actions (eg, sedation, analgesia, or motor or behavioural changes), distinguish the pyrrolidones from other psychoactive drug classes. The mechanisms of action of these drugs are still not fully established; indeed, different compounds in this class may have different modes of action. Interest in this drug class has recently been reawakened by the licensing of levetiracetam as a potentially major new antiepileptic drug and of piracetam for its antimyoclonic action and effects after stroke and in mild cognitive impairment. Other drugs in this class are currently at an advanced stage of development, and the renewal of interest in this therapeutic area is likely to mean not only that more pyrrolidones will enter clinical practice in the next few years but also that the clinical indications of drugs already licensed will widen. À òàì, êðîìå <<more than three decades>> - Öèòàòà:
 Ñ óâàæåíèåì, Â.Ê. |
|
#45
05.03.2005, 05:45
|
||||
|
||||
|
Óâàæàåìûé Àâèàòîð.
Ïàðó çàìå÷àíèé î êîñìîíàâòàõ. Ýòî âåäü òîæå ìåäèöèíñêèé ýêñïåðèìåíò ñ î÷åíü æåñòêèìè óñëîâèÿìè. Òî, ÷òî èñïîëüçóåòñÿ ïðåïàðàòû ñ íîîòðîïíûì äåéñòâèåì - âîçìîæíî. À âîò â òî, ÷òî èñïîëüçóþòñÿ ÷èñòûå íîîòðîïû - ñîìíåâàþñü. Íàïðèìåð ôåíèáóò - ñ íîîòðîïíûì ýôôåêòîì, íî ïðåæäå âñåãî ñ òðàíêâèëèçèðóþùèì äåéñòâèåì.  ïðàêòèêå ÿ ñòàëêèâàëñÿ ñ âûðàæåííîé òðåâîãîé ( âïëîòü äî ñòðàõà) âîçíèêøåé ïîñëå ïðèåìà áîëüøèõ äîç íîîòðîïèëà è èìåííî ó ñòóäåîðîâ... |
Ëèíåéíûé âèä
